EAM
BBOT

Eventide Asset Management’s BridgeBio Oncology BBOT Stock Holding History

Eventide Asset Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-541,181
Closed -$4.7M – 336
2026
Q1 		$4.7M Sell
541,181
-541,181
-50% -$5.81M 0.08% 165
2025
Q4 		$13.4M Hold
1,082,362
– – 0.21% 125
2025
Q3 		$12.4M Buy
+1,082,362
New +$11.3M 0.2% 119

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Eventide Asset Management's BBOT Position: Q2 2026 in Review

Eventide Asset Management sold out of BridgeBio Oncology (BBOT) in Q2 2026, closing a stake of 541,181 shares — an estimated $4.7M sold.

Eventide Asset Management first reported a position in BBOT in Q3 2025 and held it in 3 quarters. The position peaked at $13.4M in Q4 2025. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Eventide Asset Management reported no remaining BridgeBio Oncology position as of Q2 2026 after selling out during the quarter.
  • Eventide Asset Management sold 541,181 BridgeBio Oncology shares in Q2 2026, an estimated $4.7M.
  • Eventide Asset Management first reported a position in BridgeBio Oncology in Q3 2025 and held it in 3 quarters.
  • Eventide Asset Management's BridgeBio Oncology position peaked at $13.4M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.